Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05431270 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
A Phase 1 study of Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by Phanes Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 6
- Study locations
NCT05431270: Recruiting Phase 1 study of Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by Phanes Therapeutics.
NCT05431270 is a Phase 1 study of Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by Phanes Therapeutics. The registered enrollment target is 40 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (94% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05431270, a Phase 1 study of Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by Phanes Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a first-in-human, Phase 1/2, open-label, study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Mavrostobart (PT199) alone and in combination with a PD-1 inhibitor or chemotherapy.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Pemetrexed
- DRUG Tislelizumab
- DRUG Mavrostobart (PT199)
- DRUG Gemcitabine + nab-Paclitaxel
Study Locations (6)
Texas
- The University of Texas MD Anderson Cancer Center - Houston
- Tranquility Research - Webster
North Carolina
- Carolina BioOncology Institute - Huntersville
Oklahoma
- Sarah Cannon Research Institute University of Oklahoma - Oklahoma City
Tennessee
- SCRI Oncology Partners - Nashville
Virginia
- NEXT Oncology - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-08-11 |
| Est. Completion | 2028-08 |
| Phase | Phase 1 |
What NCT05431270 shows while recruiting
NCT05431270 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Docetaxel is the first listed.
NCT05431270 lists 6 locations in 5 states (Texas, North Carolina, Oklahoma).
Frequently Asked Questions
What is clinical trial NCT05431270 about?
NCT05431270 is a clinical study titled "Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)". This is a first-in-human, Phase 1/2, open-label, study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Mavrostobart (PT199) alone and in combination with a PD-1 inhibitor or chemotherapy.
What is the current status of trial NCT05431270?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2022-08-11. Estimated completion is 2028-08.
What conditions does trial NCT05431270 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma.
What interventions are being tested in trial NCT05431270?
The interventions under investigation include: Docetaxel (DRUG), Pemetrexed (DRUG), Tislelizumab (DRUG), Mavrostobart (PT199) (DRUG), Gemcitabine + nab-Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT05431270?
This trial is sponsored by Phanes Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05431270 being conducted?
This trial has 6 study locations across North Carolina, Oklahoma, Tennessee, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05431270's enrollment target sits among peer trials
40 360th of 454 higher than 87 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI